Trial Profile
A retrospective study analyzing efficacy and safety of anlotinib combined with TEC in neo-adjuvant treatment for locally advanced TNBC
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Feb 2023
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 16 Feb 2023 stage 2b is considered as early breast cancer (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/early-stage-breast-cancer)
- 13 Feb 2023 New trial record